KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Key facts
- Study ID
- NCT07596693
- Run by
- TCRx Therapeutics Co.Ltd
- People needed
- 30
- Starts
- 2025-12-19
- Expected to finish
- 2029-12-31
- Last updated by the study team
- 2026-05-19
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.